Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jun;71(6):1283–1287. doi: 10.1038/bjc.1995.248

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

S De Placido 1, F Perrone 1, C Carlomagno 1, A Morabito 1, C Pagliarulo 1, R Lauria 1, A Marinelli 1, M De Laurentiis 1, E Varriale 1, G Petrella 1, et al.
PMCID: PMC2033842  PMID: 7779724

Abstract

The aim of this study was to test the hypothesis of Goldie and Coldman that the use of non-cross-resistant regimens of chemotherapy could lead to maximal anti-tumour effect. We compared standard CMF (cyclophosphamide, methotrexate, fluorouracil) with alternating CMF/EV (epirubicin, vincristine) in the adjuvant therapy of early breast cancer. Stage II premenopausal node-positive or post-menopausal node-positive oestrogen receptor-negative and stage III breast cancer patients were eligible for the study. From January 1985 to December 1990, 220 patients were randomised (115 to CMF and 105 to CMF/EV). Toxicity was mild; neurotoxicity, vomiting and hair loss were more frequent in the CMF/EV group, while permanent amenorrhoea, diarrhoea, stomach ache and minor infections occurred more often in the CMF arm. At a follow-up of 48 months, 113 patients (51.4%) had had recurrence (62 on CMF and 51 on CMF/EV) and 54 (24.5%) had died (30 on CMF and 24 on CMF/EV). There was no significant difference in disease-free and overall survival between the two arms. After adjusting for menopausal status and stage, the relative risk (RR) of recurrence for CMF/EV patients was 0.93 (95% CL 0.64-1.35), while the RR of death was 0.85 (95% CL 0.49-1.47). In conclusion, the Goldie-Coldman model of alternating therapy is not confirmed in this trial of adjuvant therapy of early breast cancer, although in view of its design a difference of less than 20% in 3 year disease-free survival could not be excluded.

Full text

PDF
1283

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianco A. R., De Placido S., Gallo C., Pagliarulo C., Marinelli A., Petrella G., D'Istria M., Delrio G. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet. 1988 Nov 12;2(8620):1095–1099. [PubMed] [Google Scholar]
  2. Bianco A. R., Del Mastro L., Gallo C., Perrone F., Matano E., Pagliarulo C., De Placido S. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991 May;63(5):799–803. doi: 10.1038/bjc.1991.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976 Feb 19;294(8):405–410. doi: 10.1056/NEJM197602192940801. [DOI] [PubMed] [Google Scholar]
  4. Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739–746. doi: 10.7326/0003-4819-104-6-739. [DOI] [PubMed] [Google Scholar]
  5. Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478–1484. doi: 10.1056/NEJM199211193272102. [DOI] [PubMed] [Google Scholar]
  6. De Lena M., Brambilla C., Morabito A., Bonadonna G. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer. 1975 Apr;35(4):1108–1115. doi: 10.1002/1097-0142(197504)35:4<1108::aid-cncr2820350414>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. De Placido S., Gallo C., Marinelli A., Perrone F., Pagliarulo C., Petrella G., Delrio G., D'Istria M., Del Mastro L., Bianco A. R. Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. Breast Cancer Res Treat. 1990 Sep;16(2):111–117. doi: 10.1007/BF01809295. [DOI] [PubMed] [Google Scholar]
  8. Evans W. K., Feld R., Murray N., Willan A., Coy P., Osoba D., Shepherd F. A., Clark D. A., Levitt M., MacDonald A. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987 Oct;107(4):451–458. doi: 10.7326/0003-4819-107-4-451. [DOI] [PubMed] [Google Scholar]
  9. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855–861. doi: 10.1093/jnci/83.12.855. [DOI] [PubMed] [Google Scholar]
  10. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  11. Goodman G. E., Crowley J. J., Blasko J. C., Livingston R. B., Beck T. M., Demattia M. D., Bukowski R. M. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol. 1990 Jan;8(1):39–47. doi: 10.1200/JCO.1990.8.1.39. [DOI] [PubMed] [Google Scholar]
  12. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  13. Jain K. K., Casper E. S., Geller N. L., Hakes T. B., Kaufman R. J., Currie V., Schwartz W., Cassidy C., Petroni G. R., Young C. W. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 Jun;3(6):818–826. doi: 10.1200/JCO.1985.3.6.818. [DOI] [PubMed] [Google Scholar]
  14. Kennealey G. T., Boston B., Mitchell M. S., Knobf M. K., Bobrow S. N., Pezzimenti J. F., Lawrence R., Bertino J. R. Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin. Cancer. 1978 Jul;42(1):27–33. doi: 10.1002/1097-0142(197807)42:1<27::aid-cncr2820420105>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  15. Longo D. L., Duffey P. L., DeVita V. T., Jr, Wiernik P. H., Hubbard S. M., Phares J. C., Bastian A. W., Jaffe E. S., Young R. C. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol. 1991 Aug;9(8):1409–1420. doi: 10.1200/JCO.1991.9.8.1409. [DOI] [PubMed] [Google Scholar]
  16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. Nemoto T., Horton J., Simon R., Dao T. L., Rosner D., Cunningham T., Sponzo R., Snyderman M. Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer. 1982 May 15;49(10):1988–1993. doi: 10.1002/1097-0142(19820515)49:10<1988::aid-cncr2820491007>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  19. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988 Dec 15;48(24 Pt 1):7067–7071. [PubMed] [Google Scholar]
  20. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986 Jan;70(1):163–169. [PubMed] [Google Scholar]
  21. Palshof T., Mouridsen H. T., Daehnfeldt J. L. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials. Eur J Cancer. 1980;Suppl 1:183–187. [PubMed] [Google Scholar]
  22. Roth B. J., Johnson D. H., Einhorn L. H., Schacter L. P., Cherng N. C., Cohen H. J., Crawford J., Randolph J. A., Goodlow J. L., Broun G. O. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992 Feb;10(2):282–291. doi: 10.1200/JCO.1992.10.2.282. [DOI] [PubMed] [Google Scholar]
  23. Tormey D. C., Gelman R., Band P. R., Sears M., Rosenthal S. N., DeWys W., Perlia C., Rice M. A. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1982 Oct 1;50(7):1235–1244. doi: 10.1002/1097-0142(19821001)50:7<1235::aid-cncr2820500703>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  24. Tormey D. C., Gray R., Abeloff M. D., Roseman D. L., Gilchrist K. W., Barylak E. J., Stott P., Falkson G. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1992 Dec;10(12):1848–1856. doi: 10.1200/JCO.1992.10.12.1848. [DOI] [PubMed] [Google Scholar]
  25. Tormey D., Gelman R., Falkson G. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. Am J Clin Oncol. 1983 Feb;6(1):1–18. [PubMed] [Google Scholar]
  26. Vogel C. L., Smalley R. V., Raney M., Krauss S., Carpenter J., Velez-Garcia E., Fishkin E., Raab S., Moore M. R., Stagg M. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. J Clin Oncol. 1984 Jun;2(6):643–651. doi: 10.1200/JCO.1984.2.6.643. [DOI] [PubMed] [Google Scholar]
  27. Wolf M., Pritsch M., Drings P., Hans K., Schroeder M., Flechtner H., Heim M., Hruska D., Mende S., Becker H. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J Clin Oncol. 1991 Apr;9(4):614–624. doi: 10.1200/JCO.1991.9.4.614. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES